Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Florence

Showing results (81-90 of 116) with videos related to

Pageof 12
Sort By:
AIDS (London, England)|December 14, 2011
mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patientsEllen Van Gulck, Erika Vlieghe, Marc Vekemans, et al.
Journal of Hepatology|December 12, 2018
8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)Anne Boerekamps, Thomas Vanwolleghem, Marc van der Valk, et al.
AIDS (London, England)|September 29, 2022
Qualitative plasma viral load determination as a tool for screening of viral reservoir size in PWHThessa Laeremans, Sigrid D'haese, Jonathan Aernout, et al.
Antimicrobial Agents and Chemotherapy|October 24, 2023
A truncated HIV Tat demonstrates potent and specific latency reversal activityEllen Van Gulck, Marion Pardons, Erik Nijs, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
BMC Health Services Research|January 3, 2022
A public health value-based healthcare paradigm for HIVSebastian Vermeersch, Rémy P Demeester, Nathalie Ausselet, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Antimicrobial Agents and Chemotherapy|July 2, 2024
Correction for Van Gulck et al., "A truncated HIV Tat demonstrates potent and specific latency reversal activity"Ellen Van Gulck, Marion Pardons, Erik Nijs, et al.
Vaccines|December 11, 2019
Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMixWesley de Jong, Lorna Leal, Jozefien Buyze, et al.
AIDS (London, England)|October 6, 2018
Variation in antiretroviral treatment coverage and virological suppression among three HIV key populationsKamilla Grønborg Laut, Leah Shepherd, Magnus Gottfredsson, et al.
Pageof 12

Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
AIDS (London, England)|December 14, 2011
mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patientsEllen Van Gulck, Erika Vlieghe, Marc Vekemans, et al.
Journal of Hepatology|December 12, 2018
8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)Anne Boerekamps, Thomas Vanwolleghem, Marc van der Valk, et al.
AIDS (London, England)|September 29, 2022
Qualitative plasma viral load determination as a tool for screening of viral reservoir size in PWHThessa Laeremans, Sigrid D'haese, Jonathan Aernout, et al.
Antimicrobial Agents and Chemotherapy|October 24, 2023
A truncated HIV Tat demonstrates potent and specific latency reversal activityEllen Van Gulck, Marion Pardons, Erik Nijs, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
BMC Health Services Research|January 3, 2022
A public health value-based healthcare paradigm for HIVSebastian Vermeersch, Rémy P Demeester, Nathalie Ausselet, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Antimicrobial Agents and Chemotherapy|July 2, 2024
Correction for Van Gulck et al., "A truncated HIV Tat demonstrates potent and specific latency reversal activity"Ellen Van Gulck, Marion Pardons, Erik Nijs, et al.
Vaccines|December 11, 2019
Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMixWesley de Jong, Lorna Leal, Jozefien Buyze, et al.
AIDS (London, England)|October 6, 2018
Variation in antiretroviral treatment coverage and virological suppression among three HIV key populationsKamilla Grønborg Laut, Leah Shepherd, Magnus Gottfredsson, et al.
Pageof 12